Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
1 finding from 1 review
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Death during study period · people with liver metastases
It is very uncertain whether transarterial embolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
1 finding from 1 review
Disease control rate · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes disease control rate compared with sorafenib (very low certainty).
1 finding from 1 review
Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma
Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes serious adverse events compared with chemoembolisation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
1 finding from 1 review